Emergent BioSolutions Stock

Emergent BioSolutions ROA

The Return on Assets (ROA) of Emergent BioSolutions (EBS) as of Aug 25, 2026 is 3.99 %. In the previous year, Return on Assets (ROA) was -13.72 % — a change of -129.09% (higher).

ROA

3.99 %

YoY

-129.09%

Last updated:

In 2026, Emergent BioSolutions's return on assets (ROA) was 3.99 %, a -129.09% increase from the -13.72 % ROA in the previous year.

The Emergent BioSolutions ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
2.81 USD
Jan 1, 2019
2.34 USD
Jan 1, 2020
10.61 USD
Jan 1, 2021
7.42 USD
Jan 1, 2022
-6.68 USD
Jan 1, 2023
-41.71 USD
Jan 1, 2024
-13.72 USD
Jan 1, 2025
3.99 USD
The Emergent BioSolutions ROA history
YEARROAYoY
3.99 %-129.09%
-13.72 %-67.12%
-41.71 %+524.17%
-6.68 %-190.05%
7.42 %-30.03%
10.61 %+352.92%
2.34 %-16.73%
2.81 %-63.56%
7.72 %+44.55%
5.34 %-11.37%
6.02 %+54.99%
3.89 %
Access this data via the Eulerpool API

Emergent BioSolutions Stock analysis

What does Emergent BioSolutions do? Emergent BioSolutions Inc is a biotechnology company specializing in the development of products for protection against biological threats, infectious diseases, and cancer. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland, USA. Emergent BioSolutions' business model is based on developing and marketing innovative products for the protection of public health and national security. The company aims to respond to known and unknown threats and focus on the changing healthcare needs of society. Emergent BioSolutions operates in four business segments: Biosavérica, Vaccines, Therapeutics, and Contract Manufacturing. Biosavérica is a Latin American subsidiary specializing in the distribution of biological products in Central and South America. Vaccines develops and produces vaccines for infectious diseases such as anthrax, cholera, and typhoid. Therapeutics focuses on the development of anti-infectives and cancer therapeutics. Contract Manufacturing offers services to the biopharmaceutical industry, including the manufacturing, development, and analysis of biopharmaceutical products. Emergent BioSolutions' products include vaccines, antitoxins, antibodies, and therapeutics. One of their most well-known products is BioThrax, an anthrax vaccine used by the US government for defense against biological threats since 2002. Other products include the cholera vaccine Vaxchora, the flu medication FluBlok, and the antibody Anthim used for anthrax. Emergent BioSolutions has partnerships with various governments and organizations worldwide, including the US government, the European Commission, and the World Health Organization. This collaboration aims to ensure that Emergent BioSolutions provides products and services in the areas of national security and public health and enables a rapid response in the event of epidemics and pandemics. In recent years, Emergent BioSolutions has also made several acquisitions to strengthen its business. In 2017, they acquired Cangene Corporation, a company specialized in the manufacture of anti-infectives and antitoxins. In 2019, Emergent BioSolutions acquired PaxVax, a company developing vaccines for infectious diseases, and Adapt Pharma, a company specializing in antidotes for opioid overdose. Emergent BioSolutions is a company focused on innovative research and development, offering products for the protection of public health and national security. The company has experienced significant growth in recent years and strives to adapt to the changing healthcare needs of society. Emergent BioSolutions is one of the most popular companies on Eulerpool.

ROA Details

Understanding Emergent BioSolutions's Return on Assets (ROA)

Emergent BioSolutions's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Emergent BioSolutions's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Emergent BioSolutions's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Emergent BioSolutions’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Emergent BioSolutions stock

Return on Assets (ROA) of Emergent BioSolutions is 3.99 % in 2026.

Return on Assets (ROA) of Emergent BioSolutions changed from -13.72 % to 3.99 %, representing a -129.09% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Emergent BioSolutions since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Emergent BioSolutions with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

Profitability — Emergent BioSolutions

All Key Metrics — Emergent BioSolutions